Physician profile
John Herion
NPI 1629024898
$1,799.57
in general payments reported to CMS, 2019-2025
22 companies · $641 in 2025
The $641 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $32.57 · 2021: $187 · 2022: $244 · 2023: $235 · 2024: $338 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210 · Education: $4.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.86 |
| Education | $4.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.42 | 2021-2025 | Farxiga, Lokelma |
| Nxstage Medical, INC. | $392.24 | 2022-2025 | Nxstage System One |
| Amgen INC. | $143.70 | 2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $124.65 | 2019-2025 | Voyxact |
| Akebia Therapeutics INC | $119.29 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.64 | 2025 | Jardiance |
| Sandoz INC. | $54.96 | 2023-2024 | Hyrimoz |
| Travere Therapeutics, INC. | $49.68 | 2024-2025 | |
| Daiichi Sankyo INC. | $49.60 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $49.26 | 2025 | |
| Alexion Pharmaceuticals, INC. | $36.69 | 2025 | Ultomiris |
| Horizon Therapeutics Plc | $36.27 | 2019-2020 | |
| Baxter Healthcare | $33.30 | 2021-2024 | Renal - Acute |
| E.R. Squibb & Sons, L.L.C. | $32.16 | 2024-2025 | Orencia |
| Calliditas Therapeutics US INC. | $25.38 | 2025 | Tarpeyo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $23.96 | 2025 | Ozempic |
| Ucb, INC. | $23.78 | 2023 | Cimzia |
| Janssen Biotech, INC. | $22.55 | 2023 | Remicade, Tremfya, Simponi Aria |
| Lilly USA, LLC | $21.54 | 2024 | Jardiance |
| Vifor Pharma, INC. | $19.46 | 2022 | |
| Fresenius USA Marketing, INC. | $19.06 | 2025 | Velphoro |
| Aurinia Pharma U.S., INC. | $16.98 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Herion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.